French Biotech CellVax is Now Able to Propose Preclinical Studies in Large Animals

• CellVax announces today it has signed strategic
  partnership with 2 large Chinese pharmaceutical companies:
  Medtech OSMUNDA, a worldwide leading clinical trial CRO and service
  provider of medical devices, and big pharmaceutical actor: Guangzhou
  General Pharmaceutical Research Institute.
• CellVax is now able to propose to its European customers new standards
  for preclinical and clinical studies, with large nonrodent
  animals models
• Qualifying strategy to meet international standards of
  scientific quality control
• Public & private financing underway to support
  CellVax’s strong growth.

MAISON-ALFORT, France–(BUSINESS WIRE)–Thanks to this strategic partnership, CellVax
can now respond to the strong demand for optimal selection
of models that represent the human disease best and is able
to offer preclinical studies in large nonrodent species as
well as diversified preclinical models or clinical trials.
Large
animal models are essential for the development of novel
therapeutics for Cancer and Osteoarthritis (OA) fields, the two
research specialties of CellVax. Through this partnership, the company
has achieved a significant progress in its capacity to provide
wide range of animal models for these diseases.
From now
on, CellVax offers to fully realize high value-added projects in
China and France / Europe, including product registrations
in China for European clients, or a better understanding of
European markets for Chinese clients.

Quicker funding to support the growth and to finance quality and R&D
resources, innovation driver for CellVax
Since February 2019,
CellVax has made a strong commitment to enhance the quality of its
preclinical studies. Currently, one large GLP toxicology and
Bio-distribution study is ongoing at CellVax.
By the end of
2019, CellVax will be able to perform a full range of GLP-compliant
preclinical studies in large and small animals for the development of
drugs, vaccines and medical devices.

Furthermore, CellVax is fully invested in numerous large-scale
European collaborative research programs such as Eureka, FP-7,
and Horizon 2020, as well as in the search for new ways of private
/ public financing in order to continually enhance its R&D
capability and to increase its visibility worldwide.

About CellVax – www.cellvax-pharma.com
Founded
in 2001, Cellvax is a preclinical Contract Research Organization (CRO)
which provides innovating drug validation studies both in vitro and in
vivo allowing to accelerate the drug development process for unmet needs
related to severe human diseases, mainly in Cancer and Osteoarthritis
fields. In addition to preclinical studies, CellVax provides high
quality consulting services in order to optimize the discovery process
of candidate compounds.

Contacts

CELLVAX
Dr. Mingxing WEI, CEO
+33 (0) 671434751
(France); +86 182 271 08395 (China)
[email protected]

FIN’EXTENSO
Press Relations
Isabelle Aprile
+33
1 39 97 61 22
[email protected]